Resources

2021.06
Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer

1.jpg

2.jpg

3.jpg

4.jpg

5.jpg

6.jpg

7.jpg

8.jpg

9.jpg

10.jpg

11.jpg

nment with high mutational burden in lung cancer_12.jpg

nment with high mutational burden in lung cancer_13.jpg

nment with high mutational burden in lung cancer_14.jpg

nment with high mutational burden in lung cancer_15.jpg

nment with high mutational burden in lung cancer_16.jpg

nment with high mutational burden in lung cancer_17.jpg

nment with high mutational burden in lung cancer_18.jpg

nment with high mutational burden in lung cancer_19.jpg

nment with high mutational burden in lung cancer_20.jpg

Pictures are from Journal for ImmunoTherapy of Cancer.
Nivolumab-associated DRESS in a genetic susceptible individual
Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers